Eckert & Ziegler SE's ROE % for the quarter that ended in Mar. 2026 was 15.95%. Eckert & Ziegler SE's PB Ratio for the quarter that ended in Mar. 2026 was 3.41.
Eckert & Ziegler SE's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 4.68%.
Eckert & Ziegler SE ROE % Adjusted to Book Value Related Terms
Eckert & Ziegler SE ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eckert & Ziegler SE ROE % Adjusted to Book Value Chart
XTER:EUZ vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 4.68% mean?
Eckert & Ziegler SE (XTER:EUZ) has a ROE % Adjusted to Book Value of 4.68% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Eckert & Ziegler SE and its competitors.
Is Eckert & Ziegler SE's ROE % Adjusted to Book Value too high?
Eckert & Ziegler SE's current ROE % Adjusted to Book Value is 4.68%. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's ROE % Adjusted to Book Value compare to ABT and SYK?
Eckert & Ziegler SE's ROE % Adjusted to Book Value of 4.68% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Eckert & Ziegler SE and its competitors. Eckert & Ziegler SE's current ROE % Adjusted to Book Value is 4.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (XTER:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.26, compared to a current price of €15.89 — trading 2.3% below its estimated fair value. The current ROE % Adjusted to Book Value is 4.68%. Eckert & Ziegler SE's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Eckert & Ziegler SE (XTER:EUZ), the current ROE % Adjusted to Book Value is 4.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (XTER:EUZ) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.89 is trading 2.3% below its estimated GF Value™ of €16.26.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for XTER:EUZ:
ROE % Adjusted to Book Value: 4.68%
GF Value™: €16.26 vs. price of €15.89 (2.3% below fair value)
No single metric tells the full story. See the XTER:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score
Get the complete analysis for XTER:EUZ
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:EUZ has been successfully added to your 
